Which Patients Benefit from Radiation Therapy in Diffuse Large B-Cell Lymphoma in 2023? Recent Evidence and Future Developments
![](https://academy.astro.org/sites/default/files/styles/course_image_teaser/public/OnlineCourses.jpg?itok=VNNiGZcY)
The role of RT in DLBCL is changing. Recent randomized studies have challenged the role of RT in the primary treatment of DLBCL but they included selected patient populations, making application of results in routine clinical practice difficult.
Category
- Other
- Leuk/Lymph/Hema
Format
- CME only
Credits
- 1.25 AMA PRA Category 1 Credit™
- 1.25 Certificate of Attendance
ASTRO/ILROG Joint Session - When Every Centigray Counts: Expert Panelists on Approaching and Optimizing the Most Challenging Lymphoma Plans
![](https://academy.astro.org/sites/default/files/styles/course_image_teaser/public/OnlineCourses.jpg?itok=VNNiGZcY)
Ongoing advances in technology have allowed for the shrinkage of target volumes and lowering of doses in the treatment of lymphomas with radiation.
Category
- Other
- Leuk/Lymph/Hema
Format
- CME only
Credits
- 1.25 AMA PRA Category 1 Credit™
- 1.25 Certificate of Attendance
Gray Zone - Resected Diffuse Large B Cell Lymphoma: Does Extirpation Mean No Irradiation in the PET-Response based Milieu?
![](https://academy.astro.org/sites/default/files/styles/course_image_teaser/public/GrayZone_Single.jpg?itok=CYl44mSO)
The ultimate goal of radiation oncology research is to improve clinical care. As a specialty, we tackle diverse research questions, addressing every type of cancer and encompassing cancer biology and radiation physics. But despite our best efforts, evidence-based medicine cannot provide 1 clear
Category
- Leuk/Lymph/Hema
Format
- Gray Zone
Credits
- 1.00 AMA PRA Category 1 Credit™